- CA$0.44m
- -CA$0.03m
Brief: Vaxil Bio Says Proposed Reverse Takeover With Green Date Terminated
Brief: Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over
Brief: Vaxil Bio To Continue Actively Explore Other Strategic Options
Brief: Vaxil Bio Enters Into Letter Of Intent With Copper Bullet Mines In Respect Of A Proposed Reverse Takeover
Brief: Vaxil Provides Update On Research Activities And Management Changes
Brief: Vaxil Provides Final Results On Its Previously Disclosed Research With Ben-Gurion University Of The Negev
Brief: Vaxil Announces Resignation Of Director
Brief: Vaxil Bio Agreed Not To Pursue Acquisition Of Shortwave
Brief: Vaxil Signs Letter Of Intent To Acquire A 100% Interest In Short Wave Pharma Inc.
Brief: Vaxil Announces Progress On Research And Development Activities
Brief: Vaxil Announces Changes To Senior Management And Provides Updates On Current Research And Development Work
Brief: Vaxil Bio Ltd Says Put Its COVID-19 Vaccine Work On Temporary Hold
Brief: Vaxil Bio Ltd Announces CEO Resignation
Brief: Vaxil Provides Strategy Update From Conclusion Of Covid-19 Challenge Study
Brief: Vaxil Provides Update On Usamriid, Oral Experiment And Other General Business Matters
As Of Dec 30, 2020, Co Has $1.3 Million In Cash, Equivalents
Brief: Vaxil Provides Update On Usamriid And Oral Experiments
Brief: Vaxil Announces Close Of Second And Final Tranche Of Previously Announced Non-Brokered Private Placement For Gross Proceeds Of $264,100
Brief: Vaxil Provides Business Update On Corvax Experiments